-
A hitch in the stitch reveals why DNA sequence patterns matter in Huntington’s disease
Latest News
-
Worms to the Rescue: Separating the Good, the Bad, and the Clumpy Huntingtin
⏱️ 7 min read | A team of researchers developed a simple platform to test how toxic different types of HTT protein clumps are using a laboratory worm model. They showed that certain types of clumps are harmful to the worms, while others are not.
-
'Induced' stem cells make exciting advances
Stem cells from HD patients: becoming important tools for researchers – and now correcting the HD mutation in the lab
-
ASO gene silencing reaches further, lasts longer
Silencing the Huntingtin gene using ASO drugs reaches further, lasts longer and is safe. Human trial soon?
-
Phosphodiesterase inhibitors: new HD drugs entering trials soon
CHDI and Pfizer announce exciting animal work and plans for a human trial with a drug targeting 'phosphodiesterases'.
-
Interview: CHDI's scientific team
HDBuzz interviews the top scientists from CHDI, the largest funder of Huntington's disease research in the world.
-
Exercise increases cellular recycling
Exercise boosts cellular recycling in mice. Could this be why exercise is also good for HD – or even help develop dru
-
The HDBuzz Prize for young science writers
Announcing the HDBuzz Prize for young science writers!
-
What's the connection between Huntington's Disease and cancer?
HD patients are less likely to get cancer, according to a study from Sweden – what does this mean?
-
Closing the care gap: new guidelines for HD care
Closing the care gap: new guidelines to help every Huntington's disease patient get great care
-
Stem-cell neurons make the right connections
Replacing neurons in mice with stem cells works much better than expected, suggesting that replacement therapy might
-
2012 Therapeutics Conference: a retrospective
HDBuzz looks back at the 2012 Huntington's Disease Therapeutics Conference
HDBuzz Trial Tracker
Progress update for NCT06585449 – A Study to Evaluate ALN-HTT02
Additional insights from Phase 2 study results and update on plans for Phase 3 trial for votoplam
